Long-term cardiovascular and cerebrovascular morbidity in Israeli thyroid cancer survivors

Elena Izkhakov1,2,3,*, Joseph Meyerovitch2,4,5,*, Micha Barchana3, Yacov Shacham2,6, Naftali Stern1,2 and Lital Keinan-Boker3,7

1Institute of Endocrinology, Metabolism and Hypertension, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel
2Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
3School of Public Health, Faculty of Social Welfare and Health Sciences, University of Haifa, Haifa, Israel
4Community Division, Clalit Health Services, Tel Aviv, Israel
5The Jesse Z and Sara Lea Shafer Institute for Endocrinology and Diabetes, National Center for Childhood Diabetes, Schneider Children's Medical Center of Israel, Petah Tikva, Israel
6Department of Cardiology, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel
7National Cancer Registry, Israel Center for Disease Control, Ministry of Health, Israel, Ramat Gan, Israel

Correspondence should be addressed to E Izkhakov: elenaiz@tlvmc.gov.il

(*E Izkhakov and J Meyerovitch contributed equally to this work)

Abstract

Objective: Thyroid cancer (TC) survivors may be at risk of subsequent cardiovascular and cerebrovascular (CaV&CeV) morbidity. The 2009 American Thyroid Association (ATA) guidelines recommended less aggressive treatment for low-risk TC patients. The aim of this study was to assess the atherosclerotic CaV&CeV outcome of Israeli TC survivors compared to individuals with no thyroid disease, and the atherosclerotic CaV&CeV outcome before (2000–2008) and after (2009–2011) implementation of the 2009 ATA guidelines.

Methods: All members of the largest Israeli healthcare organization who were diagnosed with TC from 1/2000 to 12/2014 (study group) and age- and sex-matched members with no thyroid disease (controls) were included. Adjusted hazard ratios (HRs) and 95% confidence intervals (95% CIs) were calculated using Cox proportional hazards models.

Results: The mean follow-up was 7.6 ± 4.2 and 7.8 ± 4.1 years for the study (n = 5,677, 79% women) and control (n = 23,962) groups, respectively. The former had an increased risk of new atherosclerotic CaV&CeV events (adjusted HR 1.26, 95% CI 1.15–1.39). The 5-year incidence of CaV&CeV was lower (adjusted HR 0.49, 95% CI 0.38–0.62) from 2009 to 2011 compared to 2000 to 2008, but remained higher in the study group than in the control group (adjusted HR 1.5, 95% CI 1.14–1.69).

Conclusions: This large Israeli population-based cohort study showed greater atherosclerotic CaV&CeV morbidity in TC survivors compared to individuals with no thyroid diseases. There was a trend toward a decreased 5-year incidence of atherosclerotic CaV&CeV events among TC survivors following the implementation of the 2009 ATA guidelines, but it remained higher compared to the general population.

Introduction

Thyroid cancer (TC) usually affects young adults, the majority of whom are women. Recent trends have shown a dramatic increase in the incidence of TC (1, 2) together with high survival rates (3). The treatment protocol of TC generally consists of thyroidectomy, radioactive iodine ablation and treatment with levothyroxine...
at dosages aimed to achieve suppression of the thyroid-stimulating hormone (TSH). However, lower TSH levels in TC survivors were found to be associated with a higher risk of cardiovascular (CaV) mortality (4). Data from the Surveillance, Epidemiology and End Results program, which estimated the probability of death resulting from TC, other cancers and non-cancer causes in a cohort of 29,225 TC survivors, showed that the most frequent causes of non-cancer mortality in TC survivors were heart diseases (39%) and cerebrovascular (CeV) diseases (10.4%) (5). A Dutch case–control study revealed a 3.3-fold increase in the risk of CV mortality among TC survivors (4). Several small-scale studies of TC survivors with suppressed TSH showed impairment in cardiac structure (6, 7) and function (8, 9, 10, 11, 12), as well as a prothrombotic profile (13). An increase in the prevalence of atrial fibrillation (AF) in subjects with low TSH levels is well established (14, 15), including TC survivors with suppressed TSH (16). An increased prevalence of cardiovascular risk factors was reported for TC survivors compared to individuals matched by age, sex and birth state (17). An increased incidence of cardiovascular risk factors at 1–5 years after the diagnosis of TC and an increased risk of CaV&CeV morbidity among TC survivors have also been reported (18, 19).

The 2009 Guidelines of the American Thyroid Association recommended against radioidine ablation for microcarcinomas and low-risk carcinomas and more restrictive surgery for those patients (20). The first objective of this large population-based historical cohort study was to assess the incidence of atherosclerotic CaV and CeV morbidity in Israeli TC survivors compared to a sex- and age-matched control group with no thyroid disease, while controlling for cardiovascular risk factors and previous CaV&CeV morbidity. The second objective was to compare the 5-year incidence of CaV&CeV morbidity before and after the issuance of the revised guidelines in 2009.

**Subjects and methods**

**Study participants**

This historic cohort study was carried out within the framework of the Clalit Health Services (CHS), the largest healthcare organization in Israel that covers around 55% of the total population. Computerized medical records were reviewed of all members from age 18 years and above who were insured by CHS from January 1, 2000, to June 30, 2016. Inclusion criteria for the TC group were a diagnosis of TC between January 1, 2001, and December 31, 2014, a history of partial or total thyroidectomy and treatment with levothyroxine. The non-TC control group included CHS members without any documented history of cancer or of any thyroid dysfunction who were matched by sex and age (± 2 years) to each TC patient at a ratio of 5:1. Exclusion criteria for both groups were any primary cancer prior to study entry (other than TC for the study group), with the exception of squamous or basal cell carcinoma of the skin. Patients with significant renal impairment (creatinine above 1.5 mg/dL) from both groups were excluded from the statistical analysis because of the influence of renal failure on the clinical decision of radioactive iodine administration in the TC group. After exclusion of persons with renal failure, the ratio between the exposed and non-exposed groups became 1:4.2.

**Study design and data sources**

The following data were collected for both groups: demographic characteristics, body mass index, smoking habits, background morbidity, previous and newly diagnosed diabetes mellitus, hypertension, dyslipidemia, CaV and CeV diseases, medications during the follow-up of the study period and laboratory tests that included levels of glucose and creatinine, the lipid profile and thyroid function test results closest to study entry. The atherosclerotic CaV&CeV disease was defined by ICD code as a diagnosis recorded before and during the study period of at least one of the following conditions: ischemic heart disease, myocardial infarction, transient ischemic attack, cerebrovascular accident (stroke), carotid artery stenosis or occlusion. It also included the members having undergone one of the following procedures: percutaneous transluminal coronary angioplasty, coronary artery bypass graft or carotid endarterectomy. New-onset AF was not included as a variable.

Diabetes mellitus prior to and during the follow-up period was defined as having at least one of the following: (1) a diabetes mellitus diagnosis recorded in the CHS database; (2) two fasting plasma glucose measurements higher than 125 mg/dL; (3) a random plasma glucose measurement higher than 199 mg/dL; (4) a record of hypoglycemic medications.

Hypertension prior to and during the follow-up period was defined as having at least one of the following: (1) a hypertension diagnosis recorded in the CHS database; (2) three or more measurements of systolic blood pressure...
higher than 140 mmHg or diastolic blood pressure higher than 90 mmHg; (3) a record of hypertension medication.

Dyslipidemia prior to and during the follow-up period was defined as having at least one of the following: (1) a hyperlipidemia diagnosis recorded in the CHS database; (2) at least two plasma low-density lipoprotein cholesterol measurements higher than 160 mg/dL, a triglyceride measurement higher than 150 mg/dL or a high-density lipoprotein cholesterol level lower than 40 mg/dL for males or lower than 50 mg/dL for females; (3) a record of hypolipidemic medications.

**Ethics**

The study was approved by the Medical Ethics Committee of CHS. Exemption from obtaining signed informed consent forms was granted since the study was based on existing databases and no direct contact was made with the participants.

**Statistical analysis**

Data were analyzed with SPSS software, version 23.0 (SPSS Inc.). Significance levels were set at 0.05. Data are presented as means and standard deviations for continuous variables and as frequencies and percentages for categorical variables. Chi-square tests and independent t-tests were performed to compare the two groups for categorical and continuous variables, respectively. Multivariate analysis using a Cox regression model for time to atherosclerotic CaV&CeV event was performed, adjusted for conventional risk factors. The covariates were age, sex, hypertension, diabetes mellitus, current smoking, dyslipidemia and previous CaV or CeV disease. Survival was calculated as time from study entry to the first CaV or CeV event or to death from all causes, or to the end of the follow-up period (June 30, 2016), whichever occurred earlier. The HR and 95% CIs for the first CaV or CeV events in total, by sex, and by age groups (<44, 45 to 54, 55 to 64, 65 to 74 and >75 years) were computed using the Cox proportional hazards regression model. A subanalysis using the same models but referring to the new CaV&CeV events only was performed following the exclusion of individuals with a history of CaV&CeV disease.

**Results**

The mean follow-up periods were 7.6±4.2 and 7.8±4.1 years for the study (n=5,677) and the control (n=23,962) groups, respectively. The characteristics of both groups were similar following age and sex matching, although the study group had a slightly higher proportion of men (21.4 vs 20.5%) and its mean age was slightly older (50±16 vs 47±15 years) than the control group due to the exclusion of members with renal failure (Table 1).

At baseline, the prevalence of both hypertension and dyslipidemia was higher in the study group compared to non-thyroid cancer participants with available data 13,077 (54%); number of the thyroid cancer survivors with available data 2658 (46.8%).

### Table 1 Baseline characteristics of the non-thyroid cancer and thyroid cancer survivors groups.

|                  | Non-thyroid cancer group (n = 23,962) | Thyroid cancer survivors group (n = 5677) |
|------------------|--------------------------------------|-----------------------------------------|
| Male sex, n (%)  | 4912 (20.5)                          | 1216 (21.4)                             |
| Age (years)      |                                      |                                         |
| Mean (s.d.)      | 47 (15)                              | 50 (16)                                 |
| Median (range)   | 46 (18–100)                          | 49 (18–108)                             |
| Smoking          |                                      |                                         |
| Past, n (%)      | 1249 (5.2)                           | 371 (6.5)                               |
| Current, n (%)   | 6080 (25.4)                          | 947 (16.7)                              |
| Never or no      | 16,633 (69.4)                        | 4359 (76.8)                             |
| response, n (%)  |                                      |                                         |
| Weight, mean (s.d.) (kg) | 76 (21)$^a$ | 78 (21)$^a$                           |
| Height, mean (s.d.) (cm) | 163 (8.6) | 164 (8.7)                             |
| BMI, mean (s.d.), kg/m$^2$ | 28.0 (6.8)$^a$ | 28.5 (6.5)$^a$ |
| <18.5, n (%)     | 256 (2.0)                            | 38 (1.4)                                |
| 18.5–24.99, n (%)| 4527 (34.7)                          | 820 (30.9)                              |
| 25–29.99, n (%)  | 4221 (32.4)                          | 893 (33.7)                              |
| ≥30, n (%)       | 4031 (30.9)                          | 900 (33.9)                              |
| SBP, mean (s.d.), mmHg | 122 (16)  | 123 (15)                               |
| DBP, mean (s.d.), mmHg | 74.6 (10.6) | 75.4 (9.0)                            |
| Pulse, mean (s.d.), beat/min | 76 (10.4)  | 76 (10.2)                              |
| Cerebrovascular disease$^e$, n (%) | 624 (2.6)  | 53 (0.9)                               |
| Cardiovascular disease$^e$, n (%) | 1330 (5.6) | 119 (2.1)                             |
| Composite variable$^e$, n (%) | 1631 (6.8) | 154 (2.7)                              |
| Hypertension, n (%) | 4647 (19.3) | 1405 (24.7)                           |
| Diabetes, n (%)  | 2694 (11.2)                          | 707 (12.5)                              |
| Dyslipidemia, n (%) | 6855 (28.5)  | 1865 (33.0)                           |
| Fatty liver, n (%) | 285 (1.2)   | 101 (1.8)                              |
| Atrial fibrillation, n (%) | 119 (0.5)  | 170 (0.3)                              |
| Rheumatic disease, n (%) | 17 (0.1)   | 8 (0.1)                                |

$^a$Transient ischemic attack, cerebral vascular attack, carotid artery stenosis and occlusion, carotid endarterectomy; $^b$ischemic heart disease, acute myocardial infarction, percutaneous transluminal coronary angioplasty, coronary artery bypass graft; $^c$composite variable of atherosclerotic cerebrovascular and cardiovascular disease; $^d$number of the non-thyroid cancer participants with available data 13,077 (54%); $^e$number of the thyroid cancer survivors with available data 2658 (46.8%).

BMI, body mass index; DBP, diastolic blood pressure; SBP, systolic blood pressure; s.d., standard deviation.
the controls (24.7 vs 19.3% and 33.0 vs 28.5%, respectively, \( P < 0.05 \) for both), while the prevalence of atherosclerotic CaV&CeV morbidity in the study group was lower (2.7% (154/5677) vs 6.8% (1631/23,962), respectively, \( P < 0.001 \)). The mean baseline levels of the laboratory tests, including glucose, lipid profile and kidney function, were similar for the two groups.

During the study period, 555 (9.8%) participants with TC and 1856 (7.7%) participants without TC had new or recurrent CaV&CeV events. In parallel, hypertension and dyslipidemia were higher in the former compared to the latter group (11.7 vs 9.6% and 22 vs 19.7%, respectively, \( P < 0.001 \) for both) during the follow-up period.

The following factors were associated with a higher risk of new atherosclerotic CaV&CeV events in both groups in the univariate Cox regression analysis: a diagnosis of TC (HR 1.27, 95% CI: 1.14–1.42), older age (per each 1-year increment, HR 1.06, 95% CI: 1.06–1.07), male sex (HR 1.59, 95% CI: 1.45–1.74), previous CaV&CeV morbidity (HR 1.24, 95% CI: 1.07–1.45), hypertension (HR 1.81, 95% CI: 1.63–2.00), diabetes mellitus (HR 1.63, 95% CI: 1.49–1.78) and current smoking (HR 1.55, 95% CI: 1.41–1.71). Previous dyslipidemia was a risk factor for new CaV&CeV events in the control group but not in the study group (HR 1.36, 95% CI: 1.21–1.53 vs 1.14, 95% CI: 0.92–1.42, respectively).

TC was found to be a risk factor for new cerebrovascular events (HR 1.19, 95% CI: 1.04–1.37) in a multivariate Cox regression analysis adjusted for previous atherosclerotic cerebrovascular and cardiovascular morbidity (Fig. 1) and for new cardiovascular events (HR 1.20, 95% CI: 1.08–1.34) (Fig. 2) and for new atherosclerotic CaV&CeV events (HR 1.26, 95% CI: 1.15–1.39) (Fig. 3). After exclusion of the patients in both groups with a history of CaV&CeV morbidity, the HRs in the study group remained higher for new cerebrovascular events (HR 1.16, 95% CI: 1.01–1.36), for new cardiovascular events (HR 1.18, 95% CI: 1.05–1.33)
and for new atherosclerotic CaV&CeV events (HR 1.23, 95% CI: 1.12–1.36) (Fig. 4).

Stratification by sex revealed an increased HR for new CaV&CeV events among the women in the study group with and without previous CaV&CeV morbidity (HR 1.25, 95% CI: 1.11–1.40 and HR 1.29, 95% CI: 1.14–1.46, respectively). The increased HR among men in the study group was statistically significant in the analysis that included survivors with previous CaV&CeV morbidity (HR 1.20, 95% CI: 1.01–1.42); however, the estimate lost its statistical significance in the analysis after the exclusion of survivors with previous CaV&CeV morbidity (HR 1.18, 95% CI: 0.97–1.44).

Stratification by age showed an increased risk of new atherosclerotic CaV&CeV events in the study group for the subgroups aged 55–64 years (HR 1.29, 95% CI: 1.08–1.53) and 65–74 years (HR 1.36, 95% CI: 1.14–1.61). The risk in those age groups remained elevated after the exclusion of individuals with previous CaV&CeV morbidity, (HR 1.32, 95% CI: 1.09–1.60 and HR 1.41, 95% CI: 1.16–1.72, respectively).

The time that had elapsed from TC diagnosis to the occurrence of new atherosclerotic CaV&CeV events was within 2 years for 9.5%, from 2 to 5 years for 27.2%, from 5 to 10 years for 35.8% and over 10 years for 27.5% of the TC survivors. We analyzed the data after exclusion of new CaV&CeV events that occurred during the first 2 years of follow-up in order to allow a minimal latency period and to assess long-term CaV&CeV morbidity. The HRs adjusted for cardiovascular risk factors (age, sex, hypertension, diabetes mellitus, dyslipidemia and current smoking) and for previous atherosclerotic cerebrovascular and cardiovascular morbidity (if applicable) remained increased in the study group for new cerebrovascular events (HR 1.26, 95% CI: 1.06–1.50), for new cardiovascular events (HR 1.17, 95% CI: 1.02–1.34) and for new atherosclerotic CaV&CeV events (HR 1.27, 95% CI: 1.13–1.43).

The 5-year incidence of CaV&CeV was lower following a TC diagnosis from 2009 to 2011 than from 2000 to 2008 (5.8% (63/1085) vs 8.2% (241/2939), respectively,
HR 0.52 (95% CI: 0.41–0.66)). The HR was 0.49 (95% CI: 0.38–0.62) after adjusting for age, sex and previous CaV&CeV morbidity. Between the same two study periods, the incidence of dyslipidemia declined among the TC survivors from 10.4% (305/2939) to 4.9% (53/1085), P<0.001, and the incidence of hypertension declined from 13.2% (387/2939) to 6.1% (66/1085), P<0.001. However, the HR for new CaV&CeV morbidity remained increased among the TC survivors (HR 1.29, 95% CI: 1.11–1.50 and HR 1.5, 95% CI: 1.14–1.98, respectively) in a multivariate Cox regression analysis of both study groups before and after the issuance of the revised guidelines in 2009 compared to the non-TC individuals.

Discussion

The results of this large population study demonstrated that TC was independently associated with an increased risk of atherosclerotic CaV&CeV morbidity. Our findings concur with the increased incidence of cardiovascular risk factors at 1–5 years after diagnosis of TC and with the increased risk of CaV&CeV morbidity among TC survivors reported by the Utah Cancer Survivors Study and recently observed in Korean population (17, 18, 19). Importantly, our definitions of CaV&CeV disease were more stringent than those of the Utah Cancer Survivors study, as well as being related to the events themselves rather than to the conditions associated with atherosclerotic disease (e.g., hypertension, AF). In contrast, we found a reduction in the incidence of CaV&CeV morbidity, as well as a parallel decreased incidence of dyslipidemia and hypertension among TC survivors diagnosed during 2009 to 2011 when the ATA guidelines for less aggressive treatment were followed compared to 2000 to 2008 before they had been introduced. However, the incidence of CaV&CeV morbidity remained higher for the TC survivors compared to the non-TC individuals during those two time periods.

In the current cohort, the increased HRs for new CaV&CeV events were more prominent among TC survivors in the age groups of 55–64 years and 65–74 years and remained increased after exclusion of the individuals with previous CaV&CeV morbidity. The HR for new CaV&CeV events among the women with TC was higher before and after excluding those with previous CV&CeV morbidity at study entry. The HR for new CaV&CeV events among the men with TC was higher before but not after excluding those with previous CaV&CeV morbidity at study entry. Since men comprised only 21% of the cohort, the smaller numbers may be a reason for the lack of statistical significance.

There are several explanations for the new trends in the incidence of CaV&CeV morbidity in TC survivors. Treatment of TC generally consists of a thyroidectomy, radioactive ablation and treatment with levothyroxine at dosages to achieve TSH suppression. La Coeur et al. observed that although the effect of radioiodine therapy on morbidity was not conclusive; however, their retrospective cohort study did reveal increased cerebrovascular events in both hyperthyroid and euthyroid patients treated with radioactive for benign thyroid disorders (21). This supports the possible contribution of radioiodine treatment to cerebrovascular morbidity by accelerating or initiating atherosclerosis. However, the same investigators were not able to detect signs of atherosclerosis in that setting and that applied to both early signs of atherosclerosis, as assessed by changes in carotid intima media thickness during the first year following radioiodine therapy, as well as late signs of atherosclerosis, as assessed by comparing the presence of plaque in patients to controls at a median of 10 years after radioiodine treatment (22). Park et al. recently reported a marginal association between radiation therapy after surgery and an elevated risk of cerebrovascular disease compared with surgery only in TC survivors (18). Sanal et al. observed carotid artery intimal thickening after RAI for benign disease (23).

TSH suppression therapy caused a state of subclinical hyperthyroidism and is a part of TC treatment. The current study does not have any data on the exact dosages of levothyroxine or the TSH-suppressive levels that were achieved. However, others have reported the contributions of the therapeutic components. A poorer cardiovascular profile has been reported among individuals with subclinical hyperthyroidism not associated with TC (24, 25, 26, 27, 28, 29, 30, 31). However, a pooled analysis of four prospective cohort studies failed to demonstrate any association between subclinical hyperthyroidism and stroke (32). Another study showed that adverse events related to arterial stiffness or central hemodynamics were not increased among TC survivors who were not treated with TSH suppression therapy when compared with a sex- and age-matched control group that did not undergo thyroidectomy (33). Similarly, no impairment in cardiac function or structure was observed among TC survivors who were treated for up to 9 years with levothyroxine therapy and whose TSH levels were higher than those recommended for TSH suppression (34). These studies suggest that levothyroxine therapy
alone (without TSH suppression) does not contribute to a poorer metabolic profile. Due to the increased risk of side effects and the limited benefits of TSH suppression in low- and intermediate-risk differentiated TC (6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 35, 36), the updated ATA 2015 guidelines advocate it solely for patients with a high risk of differentiated TC recurrence (37).

A randomized placebo-controlled trial of individuals with 10 or more years of TSH suppressive therapy for TC found that glucose and lipid metabolism remained constant and similar between those who continued TSH-suppressive therapy during a 6-month period and those whose TSH treatment was reduced to a level compatible with euthyroidism (38). During the follow-up of the current study, the incidences of both hypertension and dyslipidemia were higher in the TC group compared to the non-TC group. These findings may explain, at least in part, the increased incidence of atherosclerotic CV&CeV morbidity observed among TC survivors. An especially interesting finding in the current study was a decreased incidence of hyperlipidemia, hypertension and new CaV&CeV events in TC survivors diagnosed between 2009 and 2011 compared to those diagnosed between 2000 and 2008. We suggest that the issuance and following of ATA 2009 guidelines (and 2015 ATA guidelines) for more restrictive surgery and conservative use of RAI treatment and the resulting reduction in metabolic changes may well have contributed to this trend. It is important to note that despite the decrease in the incidence of CaV&CeV morbidity among the TC survivors in the later follow-up period, it was still higher among the TC survivors compared to the non-TC individuals in both time periods. This would appear to indicate that TC survivors compose a high-risk group for cardiovascular events.

Several limitations of this study bear mention. While the large population size and the cohort design are strengths of this study, we had no data on tumor stage or responsiveness to radiiodine therapy. A major limitation of this study is that the TSH values after surgery and those during and at the end of follow-up were not recorded. Moreover, no distinction was made between the different types of TC. Differentiated TC comprises over 90% of the cases of TC, with a considerably better prognosis than the less common TC types (medullary and anaplastic).

In conclusion, the findings of this Israeli population-based cohort study demonstrated an increased risk of new atherosclerotic CaV&CeV events among TC survivors diagnosed between 2000 and 2014 and followed up until June 30, 2016, as well as a higher incidence of hyperlipidemia and hypertension among those who developed CaV&CeV disease in comparison to individuals with no thyroid diseases during the same follow-up period. In addition, we showed a trend toward decreased new atherosclerotic CaV&CeV events, as well as a parallel decreased incidence of hyperlipidemia and hypertension in TC survivors diagnosed between 2009 and 2011 when the treatment of low-risk TC became less aggressive than that recommended in the pre-2009 ATA guidelines. However, incidence of CaV&CeV morbidity remained increased in TC survivors compared to non-TC individuals during both time periods. The clinical implications of these findings is that while less aggressive treatment of low-risk TC patients causes fewer metabolic changes in TC survivors, it still leaves them at high risk for cardiovascular events and that cardiovascular risk factors should be closely followed and perhaps more aggressively treated in this setting. Future research should define the actual risk of atherosclerotic CaV&CeV morbidity in TC survivors, the majority of whom are women, and identify early signs and effective means of prevention.

Declaration of interest
The authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of the research reported.

Funding
The study was supported by the Israel Cancer Association grant 20140135.

Acknowledgements
This study was part of a doctoral thesis (PhD) of Elena Izkhakov, MD PhD (Haifa University, Tel Aviv University), supervised by L K B and M B.

References
1 Davies L & Welch HG. Current thyroid cancer trends in the United States. JAMA Otolaryngology: Head and Neck Surgery 2014 140 317–322. (https://doi.org/10.1001/jamaoto.2014.1)
2 Konturek A, Barczynska M, Stopa M & Nowak W. Trends in prevalence of thyroid cancer over three decades: a retrospective cohort study of 17,526 surgical patients. World Journal of Surgery 2016 40 538–544. (https://doi.org/10.1007/s00268-015-3322-z)
3 La Vecchia C, Malvezzi M, Bosetti C, Garavello W, Bertuccio P, Levi F & Negri E. Thyroid cancer mortality and incidence: a global overview. International Journal of Cancer 2015 136 2187–2195. (https://doi.org/10.1002/ijc.29251)
4 Klein Hesselink EN, Klein Hesselink MS, de Rook GH, Gansevoort RT, Bakker SJ, Vredeveld EJ, van der Horst-Schippers AN, van der Horst IC, Kamphuisen PW, Plukker JT, et al. Long-term cardiovascular mortality in patients with differentiated thyroid carcinoma: an observational study. Journal of Clinical Oncology 2013 31 4046–4053. (https://doi.org/10.1200/JCO.2013.49.1043)
5 Yang L, Shen W & Sakamoto N. Population based study evaluating and predicting the probability of death resulting from thyroid cancer and other causes among patients with thyroid cancer.
Journal of Clinical Oncology 2013 31 468–474. (https://doi.org/10.1200/JCO.2012.42.4457)
6 Mercuro G, Panzuto MG, Bina A, Leo M, Cabula R, Petrini L, Pigliaru F & Mariotti S. Cardiac function, physical exercise capacity, and quality of life during long-term thyrotropin-suppressive therapy with levothyroxine: effect of individual dose tailoring. Journal of Clinical Endocrinology and Metabolism 2000 85 159–164. (https://doi.org/10.1210/jcem.85.1.6298)
7 Shargorodsky M, Serov S, Gavish D, Leibovitz E, Harpaz D & Zimlichman R. Long-term thyrotropin-suppressive therapy with levothyroxine impairs small and large artery elasticity and decreases left ventricular mass in patients with thyroid carcinoma. Thyroid 2006 16 381–386. (https://doi.org/10.1089/thy.2006.16.381)
8 Biondi B, Fazio S, Carella C, Amato G, Cattapani D, Saccà L, Bellastella A & Lombardi G. Cardiac effects of long term thyrotropin-suppressive therapy with levothyroxine. Journal of Clinical Endocrinology and Metabolism 1993 77 334–338. (https://doi.org/10.1210/jcem.77.2.8345037)
9 Fazio S, Biondi B, Carella C, Sabaiani D, Cattapani A, Panza N, Lombardi G & Saccà L. Diastolic dysfunction in patients on thyroid-stimulating hormone suppressive therapy with levothyroxine: beneficial effect of beta-blockade. Journal of Clinical Endocrinology and Metabolism 1995 80 2222–2226. (https://doi.org/10.1210/jcem.80.7.7608283)
10 Taillard V, Sardinoux M, Oudot C, Fesler P, Rugale C, Raingeard I, Renard E, Ribelet J & du Callar G. Early detection of isolated left ventricular diastolic dysfunction in high-risk differentiated thyroid carcinoma patients on TSH-suppressive therapy. Clinical Endocrinology 2011 75 709–714. (https://doi.org/10.1111/j.1365-2265.2011.04138.x)
11 Gazdag A, Nagy EV, Erdei A, Bodor M, Berta E, Szabo Z & Jenei Z. Aortic stiffness and left ventricular function in patients with differentiated thyroid cancer. Journal of Endocrinological Investigation 2015 38 133–142. (https://doi.org/10.1007/s40601-014-0143-0)
12 Abdulrahman RM, Delgado V, Hofvitiæn JC, Ng AC, Ewe SH, Marsan NA, Holman ER, Hovens GC, Corsmit EP, Romijn JA, et al. Both exogenous subclinical hyperthyroidism and short-term overt hypothyroidism affect myocardial strain in patients with differentiated thyroid carcinoma. Thyroid 2011 21 471–476. (https://doi.org/10.1089/thy.2010.0319)
13 Home MK, Singh KK, Rosenberg KG, Wessely R, Skarulis MC, Merryman PK, Callamane A, Costello R, Patterson A, Eggerman T, et al. Is thyroid hormone suppression therapy protobiotic? Journal of Clinical Endocrinology and Metabolism 2004 89 4469–4473. (https://doi.org/10.1210/jc.2004-0536)
14 Sawin CT, Geller A, Wolf PA, Belanger AJ, Baker E, Bacharach P, Wilson PW, Benjamin EJ & D’Agostino RB. Low serum thyrotropin concentrations as a risk factor for atrial fibrillation in older persons. New England Journal of Medicine 1994 331 1249–1252. (https://doi.org/10.1056/NEJM19941110311901)
15 Auer J, Scheibner P, Mische T, Langsteger W, Eber O & Eber B. Subclinical hyperthyroidism as a risk factor for atrial fibrillation. American Heart Journal 2001 142 838–842. (https://doi.org/10.1067/mhj.2001.119370)
16 Aboenowara A, Qurashi A, Sapp JL, Alqambar MH, Saric A, O’Connell CM, Rajaraman MM, Hart KD & Imran SA. Prevalence of atrial fibrillation in patients taking TSH suppression therapy for management of thyroid cancer. Clinical and Investigative Medicine 2012 35 E152–E156. (https://doi.org/10.25011/cim.v35i3.16591)
17 Blackburn BE, Ganz PA, Rowe K, Snyder J, Wan Y, Deshmukh V, Newman M, Fraser A, Smith K, et al. Aging-related disease risks among young thyroid cancer survivors. Cancer Epidemiology, Biomarkers and Prevention 2017 26 1695–1704. (https://doi.org/10.1158/1055-9966.EPI-17-0623)
18 Park J, Blackburn BE, Ganz PA, Rowe K, Snyder J, Wan Y, Deshmukh V, Newman M, Fraser A, Smith K, et al. Risk factors for cardiovascular disease among thyroid cancer survivors: finding from Utah Cancer Survivors Study. Journal of Clinical Endocrinology and Metabolism 2018 103 2468–2477. (https://doi.org/10.1210/jc.2017-02629)
19 Suh B, Shin DW, Park Y, Lim H, Yun JM, Song SO, Park JH, Cho B & Guiller E. Increased cardiovascular risk in thyroid cancer patients taking levothyroxine: a nationwide cohort study in Korea. European Journal of Endocrinology 2019 180 11–20. (https://doi.org/10.1530/EJE-18-0551)
20 American Thyroid Association (ATA) Guidelines Taskforce on Thyroid Nodules and Differentiated Thyroid Cancer, Cooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL, Mandel SJ, Mazzaferri EL, McIver PB, Pacini F, et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 2009 19 1167–1214. (https://doi.org/10.1089/thy.2009.1110)
21 La Cour JL, Jensen LT, Vej-Hansen A & Ngaard B. Radioiodine therapy increases the risk of cerebrovascular events in hyperthyroid and euthyroid patients. European Journal of Endocrinology 2015 172 771–778. (https://doi.org/10.1530/EJE-14-1105)
22 La Cour JL, Andersen UB, Sorensen CH, Nygaard B & Jensen LT. Radioiodine therapy does not change the atherosclerotic burden of the carotid arteries. Thyroid 2016 26 765–769. (https://doi.org/10.1089/thy.2015.0538)
23 Sanal B, Isik I, Kormaz M, Kucur C, Can F, Kilit TP, Kahraman C, Karac E & Kocak A. Effect of radioactive iodine therapy on carotid intima media thickness in patients with hyperthyroidism. Annals of Nuclear Medicine 2016 30 75–80. (https://doi.org/10.1007/s12149-015-1033-z)
24 Auer J, Scheibner P, Mische T, Langsteger W, Eber O & Eber B. Subclinical hyperthyroidism as a risk factor for atrial fibrillation. American Heart Journal 2001 142 838–842. (https://doi.org/10.1067/mhj.2001.119370)
25 Cappola AR, Fried LP, Arnold AM, Danese MD, Kuller LH, Burke GL, Tracy RP & Ladenson PW. Thyroid status, cardiovascular risk, and mortality in older adults. JAMA 2006 295 1033–1041. (https://doi.org/10.1001/jama.295.9.1033)
26 Collet TH, Gussekloo J, Bauer DC, den Elzen WP, Cappola AR, Balmer P, Iervasi G, Åsvold BO, Sgarbi JA, Völzke H, et al. Subclinical hyperthyroidism and the risk of coronary heart disease and mortality. Archives of Internal Medicine 2012 172 799–809. (https://doi.org/10.1001/archinternmed.2012.402)
27 Gencer B, Collet TH,Virginí V, Auer R & Rodondi N. Subclinical thyroid dysfunction and cardiovascular outcomes among prospective cohort studies. Endocrine, Metabolic and Immune Disorders: Drug Targets 2013 13 4–12. (https://doi.org/10.2174/18715303113010003)
28 Vadiveloo T, Donnan PT, Cochrane L & Leese GP. The Thyroid Epidemiology, Audit, and Research Study (TEARS): morbidity in patients with endogenous subclinical hyperthyroidism. Journal of Clinical Endocrinology and Metabolism 2011 96 1344–1351. (https://doi.org/10.1210/jc.2010-2693)
29 Kaminski G, Dziak M, Szczepanek-Parulska E, Zybek-Kock A & Buchala M. Electrocardiographic and scintigraphic evaluation of patients with subclinical hyperthyroidism during workout. Endocrine 2016 53 512–519. (https://doi.org/10.1007/s12020-016-0877-x)
30 Gencer B, Collet TH, Virginí V, Bauer DC, Gussekloo J, Cappola AR, Nanchen D, den Elzen WP, Balmer P, Luben RN, et al. Subclinical thyroid dysfunction and the risk of heart failure events: an individual participant data analysis from 6 prospective cohorts. Circulation 2012 126 1040–1049. (https://doi.org/10.1161/CIRCULATIONAHA.112.096024)
31 Selmer C, Olesen JB, Hansen ML, von Kappelgaard LM, Madsen JC, Hansen PR, Pedersen OD, Faber J, Torp-Pedersen C & Gislason GH. Subclinical and overt thyroid dysfunction and risk of all-cause mortality and cardiovascular events: a large population study. Journal
E Izkhakov, J Meyerovitch et al. Thyroid cancer and CV morbidity

of Clinical Endocrinology and Metabolism 2014 99 2372–2382. (https://doi.org/10.1210/jc.2013-4184)

32 Chaker L, Baumgartner C, Ikram MA, Dehghan A, Medici M, Visser WE, Hofman A, Rodondi N, Peeters RP & Franco OH. Subclinical thyroid dysfunction and the risk of stroke: a systematic review and meta-analysis. European Journal of Epidemiology 2014 29 791–800. (https://doi.org/10.1007/s10654-014-9946-8)

33 LaugeSEN E, Moser E, Sikjaer T, Poulsen PL & RejNMARK L. Arterial stiffness and central hemodynamics in thyroidecomized patients on long-term substitution therapy with levothyroxine. Thyroid 2016 26 779–784. (https://doi.org/10.1089/thy.2015.0600)

34 Hong KS, Son JW, Ryu OH, Choi MG, Hong JY & Lee SJ. Cardiac effects of thyrotropin oversuppression with levothyroxine in young women with differentiated thyroid cancer. International Journal of Endocrinology 2016 2016 9846790. (https://doi.org/10.1155/2016/9846790)

35 Sugitani I & Fujimoto Y. Does postoperative thyrotropin suppression therapy truly decrease recurrence in papillary thyroid carcinoma? A randomized controlled trial. Journal of Clinical Endocrinology and Metabolism 2010 95 4576–4583. (https://doi.org/10.1210/jc.2010-0161)

36 Lamartina L, Montesano T, Falcone R, Biffoni M, Grani G, Maranghi M, Ciotti L, Giacomelli I, Ramundo V, Lo Monaco C, et al. Is it worth suppressing TSH in low- and intermediate-risk papillary thyroid cancer patients before the first disease assessment? Endocrine Practice 2019 25 165–169. (https://doi.org/10.4158/EP-2018-0393)

37 Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ, Nikiforov YE, Pacini F, Randolph GW, Sawka AM, Schlumberger M, et al. 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association Guidelines task force on thyroid nodules and differentiated thyroid cancer. Thyroid 2016 26 1–133. (https://doi.org/10.1089/thy.2015.0020)

38 Heemstra KA, Smit JW, Eustatia-Rutten CF, Heijboer AC, Frolich M, Romijn JA & Corssmit EP. Glucose tolerance and lipid profile in longterm exogenous subclinical hyperthyroidism and the effects of restoration of euthyroidism, a randomised controlled trial. Clinical Endocrinology 2006 65 737–744. (https://doi.org/10.1111/j.1365-2265.2006.02660.x)

Received in final form 26 February 2019
Accepted 13 March 2019
Accepted Preprint published online 13 March 2019